Q1 2025 revenue was $38 million, flat year-over-year and down 2.7% sequentially; wholesale revenue grew 16% YoY and now represents 44% of total revenue, up from 42% last quarter.
Gross margin (non-GAAP adjusted) declined to 41.3% from 43.8% YoY, primarily due to price compression and ramp-up costs in new facilities; net loss was $5.4 million versus $1.3 million YoY.
Company expects Q2 revenue to increase in the high single digits quarter-over-quarter, driven by a full quarter of FSC revenues, promotional activities, and continued wholesale expansion, while retail softness is anticipated to persist.
Strategic focus remains on expanding brand distribution through wholesale, innovation (including new product launches like Microdose and potential hemp products), and M&A/licensing in new markets such as Delaware, Maryland, and New York.
Disciplined expense management is a priority amid challenging market conditions; company ended Q1 with $7.2 million in cash and $2.7 million in working capital, with no significant capex during the quarter.